Q4 2019 EPS Estimates for Repligen Co. Decreased by William Blair (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Equities researchers at William Blair reduced their Q4 2019 earnings per share (EPS) estimates for shares of Repligen in a research note issued on Thursday, August 1st. William Blair analyst J. Kreger now forecasts that the biotechnology company will post earnings per share of $0.19 for the quarter, down from their previous estimate of $0.20.

Several other research firms also recently weighed in on RGEN. Craig Hallum boosted their target price on Repligen from $80.00 to $108.00 and gave the company a “buy” rating in a research report on Monday. BidaskClub raised Repligen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 27th. HC Wainwright raised Repligen from a “neutral” rating to a “buy” rating and set a $110.00 target price on the stock in a research report on Monday, July 22nd. Zacks Investment Research raised Repligen from a “hold” rating to a “strong-buy” rating and set a $102.00 target price on the stock in a research report on Thursday, July 18th. Finally, ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $97.50.

NASDAQ RGEN opened at $91.36 on Monday. The company has a market cap of $4.31 billion, a P/E ratio of 125.15, a P/E/G ratio of 5.35 and a beta of 1.08. The company has a current ratio of 2.25, a quick ratio of 1.88 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average is $86.94. Repligen has a fifty-two week low of $48.26 and a fifty-two week high of $99.25.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.06. Repligen had a return on equity of 6.92% and a net margin of 11.42%. The business had revenue of $70.70 million for the quarter, compared to the consensus estimate of $65.47 million. During the same quarter in the previous year, the company posted $0.14 EPS. The company’s revenue was up 48.1% compared to the same quarter last year.

In related news, Director Karen A. Dawes sold 1,295 shares of the company’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $77.35, for a total transaction of $100,168.25. Following the completion of the sale, the director now directly owns 118,329 shares in the company, valued at approximately $9,152,748.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Glenn L. Md Cooper sold 5,000 shares of the company’s stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total value of $334,700.00. Following the sale, the director now owns 35,975 shares of the company’s stock, valued at $2,408,166.50. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of RGEN. Wells Fargo & Company MN increased its position in Repligen by 8.8% during the 2nd quarter. Wells Fargo & Company MN now owns 518,125 shares of the biotechnology company’s stock valued at $44,533,000 after buying an additional 41,749 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Repligen in the second quarter valued at about $251,000. Marco Investment Management LLC acquired a new position in shares of Repligen in the second quarter valued at about $230,000. Advisors Preferred LLC acquired a new position in shares of Repligen in the second quarter valued at about $39,000. Finally, Tygh Capital Management Inc. increased its holdings in shares of Repligen by 11.7% in the second quarter. Tygh Capital Management Inc. now owns 151,290 shares of the biotechnology company’s stock valued at $13,003,000 after purchasing an additional 15,840 shares during the period. Hedge funds and other institutional investors own 85.61% of the company’s stock.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Story: What is an Initial Public Offering (IPO)?

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.